Strategies for replacing myocytes with induced pluripotent stem in clinical protocols

Fumiyuki Hattori, Keiichi Fukuda

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Induced pluripotent stem (iPS) cells can be established via forced epigenetic reprogramming of various somatic cells and selection based on given criteria. Human iPS cells are preferred for clinical applications because they present fewer ethical concerns than embryonic stem cells. However, technical issues of stability and safety must be fully validated before clinical use. Moreover, heart regenerative therapies would require approximately 109 cardiomyocytes per person, necessitating the following technical considerations: (1) genetically and epigenetically stable scaling up of the iPS cells, (2) efficient and reproducible differentiation, and (3) highly reliable cell purification. Furthermore, (4) strategies for efficient iPS transplantation, rapid maturation, and functional integration of grafted cardiomyocytes into the host myocardium are critical unmet technologies. Herein, we discuss current progress and unmet problems for the realization of heart regenerative therapy.

Original languageEnglish
Pages (from-to)223-232
Number of pages10
JournalTransplantation Reviews
Volume26
Issue number3
DOIs
Publication statusPublished - 2012 Jul 1

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Strategies for replacing myocytes with induced pluripotent stem in clinical protocols'. Together they form a unique fingerprint.

  • Cite this